Valuation: Theracryf Plc

Market Cap 6.12M 5.36M 4.95M 4.62M 8.7M 579M 8.9M 59.54M 22.99M 285M 22.99M 22.48M 991M P/E 2026 *
-1.43x
P/E 2027 * -1.75x
Enterprise Value 3.97M 3.48M 3.21M 3M 5.64M 375M 5.77M 38.62M 14.91M 185M 14.91M 14.58M 643M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
54.35%
Yield 2026 *
-
Yield 2027 * -
1 week-8.51%
Current month-10.42%
1 month-6.52%
3 months+10.26%
6 months+7.50%
Current year+7.50%
1 week 0.21
Extreme 0.21
0.24
1 month 0.21
Extreme 0.21
0.26
Current year 0.18
Extreme 0.182
0.27
1 year 0.18
Extreme 0.175
0.3
3 years 0.18
Extreme 0.175
3.4
5 years 0.18
Extreme 0.175
9
10 years 0.18
Extreme 0.175
35
Manager TitleAgeSince
Chief Executive Officer 64 01/10/2020
Director of Finance/CFO - 05/09/2023
Chief Tech/Sci/R&D Officer - 01/05/2021
Director TitleAgeSince
Director/Board Member - 14/10/2015
Director/Board Member 64 01/10/2020
Director/Board Member - 01/01/2024
Date Insider Type Main position Quantity % Market Cap.
16/10/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
22/05/25Others

Director

422,727,272 19.8499%
04/03/25Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-8.51%-15.69%-93.28% 6.11M
+0.13%+1.50%+63.86%+123.95% 55.63B
+6.76%+22.83%+91.66%+101.42% 52.25B
+3.33%+4.51%-11.47%-11.91% 23.07B
+1.32%+6.22%+4.07%+415.45% 22.41B
+6.78%+14.47%+40.28%-6.67% 17.32B
+0.97%+5.01%+31.23%-32.10% 15.94B
-0.89%+5.71%+23.15%+186.29% 13.77B
+9.96%+19.81%+157.65%+320.70% 13.47B
+4.21%+4.76%+33.21% - 12.43B
Average +3.11%+5.30%+41.80%+111.54% 22.63B
Weighted average by Cap. +3.33%+7.62%+54.00%+128.52%

Financials

2026 *2027 *
Net sales - -
Net income -3.35M -2.93M -2.71M -2.53M -4.76M -317M -4.87M -32.6M -12.58M -156M -12.58M -12.31M -543M -3.43M -3M -2.77M -2.59M -4.87M -324M -4.98M -33.36M -12.88M -160M -12.88M -12.6M -555M
Net Debt -2.15M -1.88M -1.74M -1.62M -3.06M -203M -3.13M -20.92M -8.08M -100M -8.08M -7.9M -348M 453K 397K 367K 342K 644K 42.87M 659K 4.41M 1.7M 21.15M 1.7M 1.67M 73.43M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
29/06/26 GBX 0.2150 0.00% 1,911,416
26/06/26 GBX 0.2150 -8.51% 8,009,447
25/06/26 GBX 0.2350 0.00% 798,460
24/06/26 GBX 0.2350 0.00% 3,271,066
23/06/26 GBX 0.2350 0.00% 3,809,088
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002848USD
Average target price
0.0431USD
Spread / Average Target
+1,414.58%

Annual profits - Rate of surprise